NKTX logo

NKARTA INC

NKTXNASDAQ
🏆 #3754 by market capEarnings Nov 9US Equity
$2.63▼ $0.06 (−2.23%)
Market closed · at close
🔔
Track NKTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.2%
7d▼ 4.5%
14d▼ 8.5%
30d▼ 3.1%
ytd▲ 42.3%
1y▲ 26.2%
🏦Market Cap
$188M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
92
Very Good

Trading Snapshot

Day Range
$2.59 – $2.64
52-Week Range
$1.70 – $3.72
Volume
$1.96B
Avg Volume
$1.87B
Shares Outstanding
71.5M
Next Earnings
Nov 15, 2026

Fundamentals Snapshot

Annual Revenue
$47M
Last Q Revenue
$12M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.58
Dividend Yield
—
Dilution (1yr)
+0.6%

Why Investors Own NKTX

  • ✓High-growth profile — revenue up +52.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NKTX logo

NKARTA INC

NKTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$121M▼ −5.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$90M▼ −13.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74.0M▲ +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$37M▲ +$16M YoY
StockOtter · stockotter.space

About NKARTA INC

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
92/100

Analyst Price Target

ⓘ
Average Target
$3.23
▲ +23.0% Upside
High Target$3.98
Low Target$2.81
Based on 22 analysts

Latest News & Updates

🚀
CNBC·2h ago

NKARTA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift NKTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

NKARTA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.